Does tesamorelin reduce liver fat?

Yes. Stanley et al. 2019 (Lancet HIV) demonstrated 32% reduction in hepatic fat fraction with tesamorelin 2mg/day for 12 months in HIV-associated NAFLD. Non-HIV trials are smaller but show consistent visceral and hepatic fat reduction.

Tesamorelin dose for fatty liver research?

Published trials use 2 mg subcutaneous daily — typically administered evening before bed to align with natural GH pulse timing. Duration: 6–12 months in clinical research.

Does tesamorelin work for MASH (non-alcoholic steatohepatitis)?

Stanley 2019 showed reduced liver inflammation markers alongside fat reduction. It is not approved for MASH, but the mechanism (GHRH-driven hepatic lipid mobilisation) is mechanistically plausible and has been studied.

Tesamorelin for Fatty Liver and MASH: Complete UAE Research Review 2026

Published 23 June 2026 · REVIVE Peptides Research Desk · 9 min read

TL;DR. Stanley et al. 2019 (Lancet HIV) showed tesamorelin 2 mg/day for 12 months reduced hepatic fat fraction by 32% vs placebo in HIV-associated NAFLD. The mechanism — GHRH-driven hepatic lipid mobilisation via IGF-1 — translates plausibly to non-HIV fatty liver, though most published RCTs are in the HIV population.

Why Tesamorelin Targets Liver Fat

Tesamorelin is a GHRH (growth hormone releasing hormone) analogue. It stimulates pulsatile endogenous GH secretion, which raises IGF-1, which drives:

Visceral fat lipolysis (preferential over subcutaneous fat)
Hepatic lipid mobilisation
Free fatty acid oxidation

The visceral preference is what makes tesamorelin unique among lipolytic peptides. Most GH-related interventions reduce all body fat; tesamorelin pulls specifically from visceral and hepatic stores, the two depots most metabolically harmful.

The Stanley 2019 Liver Trial

Parameter	Detail
Citation	Stanley TL et al. Lancet HIV 2019
Design	12-month double-blind RCT
Subjects	61 adults with HIV-associated NAFLD
Dose	2 mg SC daily
Primary outcome	Hepatic fat fraction by MR spectroscopy
Result	−32% hepatic fat vs placebo +1%
Secondary outcomes	Reduced fibrosis markers, improved NAFLD activity score

Earlier Foundation — Stanley 2014

Stanley 2014 (JAMA) established the visceral fat reduction with tesamorelin in HIV lipodystrophy — 18% visceral adipose tissue reduction at 6 months. This trial preceded and predicted the liver findings. See our Stanley 2014 deep dive.

Non-HIV Fatty Liver — Smaller Trials

Most published tesamorelin liver research is in HIV populations because that's where the original FDA approval indication sits. For non-HIV NAFLD/MASH, smaller studies and case reports exist:

Bredella 2013: Showed visceral fat reduction in non-HIV abdominally obese subjects with tesamorelin.
Falutz 2010 follow-up cohort: Hepatic indicators improved alongside visceral changes.
Stanley 2012: IGF-1 dose-response in mixed-population studies.

The translation from HIV to non-HIV NAFLD assumes the mechanism (GHRH→GH→IGF-1→hepatic lipid mobilisation) operates similarly in non-HIV populations. Most experts consider this assumption reasonable but not proven.

Research Dosing

Indication	Dose	Duration	Timing
Hepatic fat research	2 mg SC daily	6–12 months	Evening
Visceral fat research	2 mg SC daily	6 months	Evening
GH/IGF-1 optimisation	1 mg SC daily	3+ months	Evening before bed

REVIVE supplies tesamorelin 5 mg and 10 mg vials. See reconstitution calculator for syringe math.

Monitoring During Research

Long-term tesamorelin research protocols typically include:

IGF-1 levels every 3 months — confirms mechanism activation; very high IGF-1 may indicate dose reduction needed
Fasting glucose / HbA1c — GH can mildly reduce insulin sensitivity
Liver enzymes (ALT/AST) — baseline and at 3, 6, 12 months
Hepatic fat imaging — MR spectroscopy or FibroScan CAP if available

Researching tesamorelin in the UAE?
REVIVE supplies tesamorelin 5 mg and 10 mg with HPLC certificates and cold-chain delivery.
View tesamorelin vials →

Tesamorelin vs GLP-1s for Liver Fat

Property	Tesamorelin	GLP-1s (retatrutide, tirzepatide)
Hepatic fat reduction	~32% (Stanley 2019)	30-50% (Loomba 2024, Sanyal 2024)
Body weight loss	Minimal	15–25%
Muscle preservation	Enhanced (anabolic GH)	At-risk (GLP-1 anorexia)
Mechanism	GHRH→IGF-1	Incretin → appetite suppression
Best research use	Liver fat with muscle preservation	Liver fat + obesity reduction

For research focused on liver fat WITHOUT weight loss — useful in lean MASH or sarcopenic obesity research — tesamorelin is uniquely positioned. Combined with GLP-1s, see our co-administration research.

Research use only. Tesamorelin supplied by REVIVE is labelled and sold strictly for in-vitro and research purposes — not for human consumption.

References

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821–e830.
Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on visceral adipose tissue and lipids in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380–389.
Falutz J, Mamputu JC, Potvin D, et al. Long-term safety and effects of tesamorelin, a GHRH analogue, in HIV patients with abdominal fat accumulation. J Clin Endocrinol Metab. 2010;95(9):4291–4304.
Bredella MA, Gerweck AV, Lin E, et al. Effects of GHRH in men with abdominal adiposity. Eur J Endocrinol. 2013;169(1):69–75.
Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311–319.